Telehealth provider Hims & Hers Health saw its stock surge more than 40% in morning trading after pharmaceutical giant Novo Nordisk dropped its patent infringement lawsuit against the company. According to CNBC, the legal battle ended after the two companies reached an agreement allowing Hims to sell Novo’s branded weight-loss drugs directly through its platform.
Terms of the New Agreement Between Hims and Novo Nordisk
Under the newly forged partnership, Hims will offer access to both injectable and oral semaglutide—marketed as Ozempic and Wegovy—at the same price points offered by other telehealth platforms, according to statements released on Monday. In exchange, Hims agreed to halt all advertising, promotion, and marketing of compounded GLP-1 drugs to the masses. Novo Nordisk CEO Mike Doustdar confirmed to CNBC that the company decided to drop current court proceedings while reserving the right to refile if necessary, though he noted he does not foresee that happening.
The settlement shifts Hims’ business model significantly. According to the company, existing patients currently using compounded semaglutide will have the opportunity to transition to FDA-approved medicines when their providers determine it is clinically appropriate. Hims will now restrict compounded versions strictly to rare cases where they are medically necessary.
Background on the Legal Dispute and FDA Scrutiny
The legal conflict began in February when Novo Nordisk announced plans to sue Hims for what it termed “mass illegal compounding.” The dispute flared after Hims advertised a copycat version of the Wegovy pill for $49, which undercut the brand-name pill by roughly $100 compared to Novo’s direct-to-consumer platform, NovoCare.
FDA Commissioner Marty Makary praised the resolution, stating on X that he was glad to see Hims stop advertising unapproved compounded drugs in favor of FDA-approved products. Makary emphasized that the platform will keep prices stable and limit compounded GLP-1s strictly to rare, FDA-compliant cases.
Hims previously capitalized on a regulatory loophole allowing companies to sell copycat versions of blockbuster drugs while official shortages persisted. Although Novo Nordisk successfully resolved its supply constraints by ramping up manufacturing, Hims continued selling alternative versions under the argument that its formulas were “personalized.” Semaglutide’s primary patent remains protected in the United States until 2032.
Market Impact and Future Outlook
The partnership marks a dramatic reversal from the companies’ previous attempt at collaboration. Last year, Novo and Hims partnered to offer discounted weight-loss medications before Novo abruptly ended the arrangement after just two months, citing deceptive marketing practices that allegedly put patient safety at risk. Addressing the renewed partnership, Doustdar told CNBC that the current environment differs entirely because Hims has agreed to eliminate mass marketing of compounded alternatives.
Hims CEO Andrew Dudum highlighted the rapidly evolving anti-obesity drug landscape during his interview with CNBC, noting that consumer demand will continue to accelerate as new product assortments emerge to address pricing, personalization, and diverse administration formats. Meanwhile, Novo Nordisk reported having more than 600,000 active scripts for the Wegovy pill, defying early competitor-fueled skepticism regarding food restrictions and uptake rates.
Related reading